We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-3%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$44.4B
AUM Growth
+$1.2B
(+2.8%)
Cap. Flow
+$3.32B
Cap. Flow
% of AUM
7.48%
Top 10 Holdings %
Top 10 Hldgs %
17.65%
Holding
2,641
New
312
Increased
1,037
Reduced
994
Closed
281
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$519M |
| 2 |
Salesforce
CRM
|
+$460M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$381M |
| 4 |
Boston Scientific
BSX
|
+$347M |
| 5 |
Intuitive Surgical
ISRG
|
+$319M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$555M |
| 2 |
Eli Lilly
LLY
|
+$536M |
| 3 |
Meta Platforms (Facebook)
META
|
+$433M |
| 4 |
Progressive
PGR
|
+$330M |
| 5 |
Lam Research
LRCX
|
+$294M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.86% |
| 2 | Healthcare | 15.38% |
| 3 | Financials | 14.3% |
| 4 | Consumer Discretionary | 11.43% |
| 5 | Industrials | 10.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2251
Inogen
INGN
$175M
| $92.7K | ﹤0.01% |
13,000
-5,700
| -30% | -$53.8K |
|
|
TOUR
2252
Tuniu
TOUR
$56.2M
| $92K | ﹤0.01% |
8,360
-2,370
| -22% | -$24.4K |
|
2253
Accuray
ARAY
$27.7M
| $91K | ﹤0.01% |
50,813
-19,700
| -28% | -$41.2K |
|
2254
TETRA Technologies
TTI
$1.05B
| $89.7K | ﹤0.01% |
26,700
-184,656
| -87% | -$736K |
|
|
MRSN
2255
DELISTED
Mersana Therapeutics
MRSN
| $88.9K | ﹤0.01% |
10,328
-7,592
| -42% | -$117K |
|
|
CLPR
2256
Clipper Realty
CLPR
$46.5M
| $87.9K | ﹤0.01% |
+22,900
| New | +$96.1K |
|
2257
Quanterix
QTRX
$161M
| $87.5K | ﹤0.01% |
13,448
-23,300
| -63% | -$194K |
|
|
MURA
2258
DELISTED
Mural Oncology
MURA
| $85.9K | ﹤0.01% |
68,200
+42,200
| +162% | +$154K |
|
2259
Adaptive Biotechnologies
ADPT
$3.57B
| $84.7K | ﹤0.01% |
11,400
-40,200
| -78% | -$309K |
|
2260
Protalix BioTherapeutics
PLX
$185M
| $84.5K | ﹤0.01% |
+33,015
| New | +$78.8K |
|
2261
Trevi Therapeutics
TRVI
$2.58B
| $83K | ﹤0.01% |
13,200
-2,700
| -17% | -$12.9K |
|
2262
Shattuck Labs
STTK
$641M
| $82.8K | ﹤0.01% |
87,100
-108,000
| -55% | -$133K |
|
2263
Arteris
AIP
$1.29B
| $81.5K | ﹤0.01% |
11,800
-11,800
| -50% | -$113K |
|
2264
ProQR Therapeutics
PRQR
$250M
| $81.1K | ﹤0.01% |
61,000
+31,800
| +109% | +$67.7K |
|
|
HSHP
2265
Himalaya Shipping
HSHP
$696M
| $80.6K | ﹤0.01% |
14,700
-1,300
| -8% | -$6.8K |
|
|
INZY
2266
DELISTED
Inozyme Pharma
INZY
| $80.4K | ﹤0.01% |
88,400
+9,700
| +12% | +$13.4K |
|
2267
NET Power
NPWR
$124M
| $79.4K | ﹤0.01% |
+30,200
| New | +$213K |
|
|
DDL
2268
Dingdong
DDL
$529M
| $79.4K | ﹤0.01% |
29,400
+15,100
| +106% | +$49.2K |
|
|
KEEL
2269
Keel Infrastructure Corp
KEEL
$2.04B
| $79.1K | ﹤0.01% |
100,387
-14,813
| -13% | -$19.6K |
|
|
ETWO
2270
DELISTED
E2open Parent Holdings
ETWO
| $78.8K | ﹤0.01% |
39,400
-1,400
| -3% | -$3.47K |
|
|
GBIO
2271
DELISTED
Generation Bio
GBIO
| $78.6K | ﹤0.01% |
19,400
-40
| -0.2% | -$281 |
|
2272
Relmada Therapeutics
RLMD
$546M
| $77.8K | ﹤0.01% |
288,000
+89,100
| +45% | +$29.5K |
|
2273
Alto Ingredients
ALTO
$342M
| $77.6K | ﹤0.01% |
68,100
-20,093
| -23% | -$31.1K |
|
|
TSVT
2274
DELISTED
2seventy bio
TSVT
| $77.1K | ﹤0.01% |
15,600
-1,700
| -10% | -$5.4K |
|
|
FFWM
2275
DELISTED
First Foundation Inc
FFWM
| $76.8K | ﹤0.01% |
14,800
-26,300
| -64% | -$141K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q1 2025 Portfolio in Review
As of Q1 2025, Two Sigma Advisers held 2,641 positions worth $44.4B, up 2.8% from $43.2B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Two Sigma Advisers deployed $3.32B of net new capital in Q1 2025, opening 312 new positions and adding to 1,037 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 553,800 shares worth $351M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Visa, an estimated $555M trimmed.
- Two Sigma Advisers's largest Q1 2025 buy was Regeneron Pharmaceuticals: 553,800 shares worth $351M.
- Two Sigma Advisers added most to Broadcom in Q1 2025, an estimated $519M increase.
- Two Sigma Advisers's biggest Q1 2025 reduction was Visa, cutting an estimated $555M.
- Two Sigma Advisers fully exited Abbott in Q1 2025, selling an estimated $158M.
- Two Sigma Advisers's ten largest holdings make up 18% of its $44.4B portfolio in Q1 2025.
- Two Sigma Advisers opened 312 new positions and closed 281 in Q1 2025.
- Two Sigma Advisers's portfolio value rose 2.8% quarter-over-quarter to $44.4B.
Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.